Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 260

1.

Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients.

Chouhfeh L, Kavak KS, Teter BE, Weinstock-Guttman B.

Mult Scler Relat Disord. 2015 May;4(3):228-33. doi: 10.1016/j.msard.2015.02.004. Epub 2015 Feb 27.

PMID:
26008939
2.

Laquinimod therapy in multiple sclerosis: a comprehensive review.

Kolb-Sobieraj C, Gupta S, Weinstock-Guttman B.

Neurol Ther. 2014 May 6;3(1):29-39. doi: 10.1007/s40120-014-0017-6. eCollection 2014 Jun. Review.

3.

A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis.

Zivadinov R, Dwyer M, Markovic-Plese S, Hayward B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Dangond F, Weinstock-Guttman B.

Ther Adv Neurol Disord. 2015 Mar;8(2):59-70. doi: 10.1177/1756285615572953.

4.

Simultaneous Determination of Oxysterols, Cholesterol and 25-Hydroxy-Vitamin D3 in Human Plasma by LC-UV-MS.

Narayanaswamy R, Iyer V, Khare P, Bodziak ML, Badgett D, Zivadinov R, Weinstock-Guttman B, Rideout TC, Ramanathan M, Browne RW.

PLoS One. 2015 Apr 13;10(4):e0123771. doi: 10.1371/journal.pone.0123771. eCollection 2015.

5.

Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.

Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F.

J Neuroimmunol. 2015 Apr 15;281:44-50. doi: 10.1016/j.jneuroim.2015.03.002. Epub 2015 Mar 5.

PMID:
25867467
6.

Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis.

Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2015 Feb 26. pii: jnnp-2014-310051. doi: 10.1136/jnnp-2014-310051. [Epub ahead of print]

PMID:
25722366
7.

Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

J Neurol Neurosurg Psychiatry. 2014 Dec 30. pii: jnnp-2014-309243. doi: 10.1136/jnnp-2014-309243. [Epub ahead of print] Review.

PMID:
25550414
8.

Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset.

Kavak KS, Teter BE, Hagemeier J, Zakalik K, Weinstock-Guttman B; on behalf of the New York State Multiple Sclerosis Consortium; on behalf of the New York State Multiple Sclerosis Consortium.

Mult Scler. 2014 Nov 12. pii: 1352458514555787. [Epub ahead of print]

PMID:
25392327
9.

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.

Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D.

J Neurol. 2015 Feb;262(2):326-36. doi: 10.1007/s00415-014-7558-6. Epub 2014 Nov 9.

PMID:
25381458
10.

Protective environmental factors for neuromyelitis optica.

Graves J, Grandhe S, Weinfurtner K, Krupp L, Belman A, Chitnis T, Ness J, Weinstock-Guttman B, Gorman M, Patterson M, Rodriguez M, Lotze T, Aaen G, Mowry EM, Rose JW, Simmons T, Casper TC, James J, Waubant E; US Network of Pediatric Multiple Sclerosis Centers.

Neurology. 2014 Nov 18;83(21):1923-9. doi: 10.1212/WNL.0000000000001001. Epub 2014 Oct 22.

PMID:
25339213
11.

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Wright S, Yadav V, Bever C Jr, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, Bourdette D, Gronseth GS, Narayanaswami P.

Neurology. 2014 Oct 14;83(16):1484-6. doi: 10.1212/01.wnl.0000455935.13606.91. No abstract available.

PMID:
25313380
12.

The US Network of Pediatric Multiple Sclerosis Centers: Development, Progress, and Next Steps.

Casper TC, Rose JW, Roalstad S, Waubant E, Aaen G, Belman A, Chitnis T, Gorman M, Krupp L, Lotze TE, Ness J, Patterson M, Rodriguez M, Weinstock-Guttman B, Browning B, Graves J, Tillema JM, Benson L, Harris Y; the US Network of Pediatric Multiple Sclerosis Centers.

J Child Neurol. 2014 Sep 30. pii: 0883073814550656. [Epub ahead of print]

PMID:
25270659
13.

Disclosure of disease status among employed multiple sclerosis patients: association with negative work events and accommodations.

Frndak SE, Kordovski VM, Cookfair D, Rodgers JD, Weinstock-Guttman B, Benedict RH.

Mult Scler. 2015 Feb;21(2):225-34. doi: 10.1177/1352458514540971. Epub 2014 Jul 28.

PMID:
25070678
14.

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

Cochrane Database Syst Rev. 2014 Jul 26;7:CD009333. doi: 10.1002/14651858.CD009333.pub2. Review.

PMID:
25062935
15.

Prospective randomized trial of venous angioplasty in MS (PREMiSe).

Siddiqui AH, Zivadinov R, Benedict RH, Karmon Y, Yu J, Hartney ML, Marr KL, Valnarov V, Kennedy CL, Ramanathan M, Ramasamy DP, Dolic K, Hojnacki DW, Carl E, Levy EI, Hopkins LN, Weinstock-Guttman B.

Neurology. 2014 Jul 29;83(5):441-9. doi: 10.1212/WNL.0000000000000638. Epub 2014 Jun 27. Erratum in: Neurology. 2014 Aug 19;83(8):773.

PMID:
24975855
16.

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.

Browne RW, Weinstock-Guttman B, Zivadinov R, Horakova D, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Qu J, Havrdova E, Ramanathan M.

J Steroid Biochem Mol Biol. 2014 Sep;143:424-33. doi: 10.1016/j.jsbmb.2014.06.007. Epub 2014 Jun 17.

PMID:
24950029
17.

MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy.

Goldberg H, Weinstock A, Bergsland N, Dwyer MG, Farooq O, Sazgar M, Poloni G, Treu C, Weinstock-Guttman B, Ramanathan M, Zivadinov R.

BMC Neurol. 2014 Jun 17;14:131. doi: 10.1186/1471-2377-14-131.

18.

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study.

Zivadinov R, Chin J, Horakova D, Bergsland N, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Hagemeier J, Tyblova M, Carl E, Krasensky J, Vaneckova M, Seidl Z, Dwyer MG, Havrdova E, Ramanathan M.

J Neuroimmunol. 2014 Aug 15;273(1-2):58-64. doi: 10.1016/j.jneuroim.2014.04.012. Epub 2014 Apr 30.

PMID:
24907902
19.

Phase white matter signal abnormalities in patients with clinically isolated syndrome and other neurologic disorders.

Hagemeier J, Heininen-Brown M, Gabelic T, Guttuso T Jr, Silvestri N, Lichter D, Fugoso LE, Bergsland N, Carl E, Geurts JJ, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2014 Oct;35(10):1916-23. doi: 10.3174/ajnr.A3969. Epub 2014 May 29.

PMID:
24874536
20.

Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions.

Gupta S, Ahsan I, Mahfooz N, Abdelhamid N, Ramanathan M, Weinstock-Guttman B.

CNS Drugs. 2014 Aug;28(8):731-42. doi: 10.1007/s40263-014-0173-3. Review.

PMID:
24871932
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk